Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN3B | O60391 | 7/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 7/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14817495 | 0.78 | GRIN3B (0.42) | GRIN3BGRIN1GRIN2CSELEVCAM1 | |
| SCHEMBL2602165 | 0.78 | PDPK1 (0.49) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL2605752 | 0.78 | GRIN3B (0.47) | GRIN3BGRIN1GRIN2CSELEVCAM1 | |
| SCHEMBL12806955 | 0.78 | GRIN3B (0.35) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL16190318 | 0.74 | GRIN3B (0.45) | GRIN3BGRIN1GRIN2C | |
| SCHEMBL13667861 | 0.74 | SELE (0.47) | SELEVCAM1ADORA1 | |
| SCHEMBL12734111 | 0.74 | GRIN3B (0.36) | GRIN3BGRIN1GRIN2CGRIN2DGRIN2A | |
| SCHEMBL14273669 | 0.72 | SELE (0.38) | SELEVCAM1ADORA1 | |
| SCHEMBL15889701 | 0.71 | MET (0.46) | — | |
| SCHEMBL15218383 | 0.71 | MAP3K8 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | GRIN3B 3419/4885GRIN1 3361/4885GRIN2C 2520/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | GRIN3B 2539/4885GRIN1 2656/4885GRIN2C 3308/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | GRIN3B 2539/4885GRIN1 2656/4885GRIN2C 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.